1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC) previously treated with antiangiogenic therapy
    Meeting Abstract

    Motzer, R. J.; Bono, P.; Hudes, G. R.; Tomita, Y.; Ravaud, A.; Waxman, I.; Gore, M. E.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D)
    Meeting Abstract

    Montgomery, R. B.; San Kheoh, T.; Molina, A.; Li, J.; Bellmunt, J.; Ryan, C. J.; Tran, N.; Loriot, Y.; Efstathiou, E.; Scher, H. I.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial
    Meeting Abstract

    Loriot, Y.; Fizazi, K.; De Bono, J. S.; Forer, D.; Hirmand, M.; Scher, H. I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Feasibility of long-term patient reporting of toxicities from home via the internet during routine chemotherapy
    Meeting Abstract

    Judson, T. J.; Bennett, A. V.; Rogak, L. J.; Sit, L.; Barz, A.; Kris, M. G.; Hudis, C.; Scher, H. I.; Sabbatini, P.; Schrag, D.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Association of hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ with UGT1A1 polymorphisms
    Meeting Abstract

    Johnson, T.; Xu, C. F.; Choueiri, T. K.; Deen, K. C.; Xue, Z.; Bartlett-Pandite, A. N.; Carpenter, C.; Motzer, R. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase I/II study of paclitaxel plus ifosfamide (TI) followed by high-dose paclitaxel, ifosfamide, and carboplatin (TIC) with autologous stem cell transplant (ASCT) for salvage treatment of germ cell tumors (GCT)
    Meeting Abstract

    Jia, X.; Feldman, D. R.; Glezerman, I.; Van Alstine, L. J.; Bajorin, D. F.; Fischer, P.; Hughes, A.; Sheinfeld, J.; Bains, M. S.; Reich, L.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer
    Meeting Abstract

    Janjigian, Y. Y.; Capanu, M.; Gromisch, C. M.; Kelsen, D. P.; Ku, G. Y.; Brown, K. T.; Schattner, M.; Ilson, D. H.; Solit, D. B.; Berger, M. F.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Rates of dose adjustment in patients treated with tivozanib versus sorafenib in the phase III TIVO-1 study
    Meeting Abstract

    Hutson, T. E.; Nosov, D.; Harza, M.; Esteves, B.; Strahs, A. L.; Berkenblit, A.; Motzer, R. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    Meeting Abstract

    Grisham, R. N.; Sala, E.; Zhou, Q.; Iasonos, A.; DeLair, D.; Iyer, G.; Hyman, D. M.; Spriggs, D. R.; Aghajanian, C.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets)
    Meeting Abstract

    Harding, J. J.; Catalanotti, F.; Yaqubie, A.; McDermott, G. C.; Kersellius, R.; Merghoub, T.; Carvajal, R. D.; D'Angelo, S. P.; Dickson, M. A.; Schwartz, G. K.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save